MSLN-positive tumor cells lacking HLA-A*02 are recognized by the activating anti-mesothelin CAR and are lysed by the engineered T cells via perforin/granzyme-mediated cytotoxicity (with cytokine effects). The HLA-A*02–specific inhibitory receptor blocks killing of HLA-A*02–positive cells.